HIGHOutside partySupplier
API sole or limited-source suppliers
“10-K Item 1: 'We currently procure the API used in our products from a sole supplier or limited number of suppliers.'”
COLL · Concentration risk · 10-K extracted
Collegium Pharmaceutical (COLL) concentration risks
Updated
The most significant concentration Collegium Pharmaceutical discloses is API sole or limited-source suppliers, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Collegium Pharmaceutical’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 4 disclosed concentrations
HIGH3
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
Patheon (contract manufacturer for Xtampza ER and Nucynta ER)
“10-K Item 1: 'To date, we have produced Xtampza ER through a contract manufacturing organization, Patheon, a subsidiary of Thermo Fisher Scientific, pursuant to a third-party supply agreement.'”
HIGHBuilt-inGeographic
United States
“10-K Item 1: 'We commercialize our products, consisting of Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the “Nucynta Products”), and Symproic, in the United States.'”
MEDIUMOutside partyCustomer
wholesale pharmaceutical distributors
“10-K Item 1A: 'We depend on wholesale pharmaceutical distributors for retail distribution of our products; if we lose any of our significant wholesale pharmaceutical distributors or their distribution network is disrupted, our financial condition and results of operations may be adversely affected.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Collegium's concentration profile is dominated by high-share dependencies rather than diversified structural exposure. On the supply side, the company sources its active pharmaceutical ingredient from a sole or limited number of suppliers, and relies on Patheon, a Thermo Fisher subsidiary, as the contract manufacturer for both Xtampza ER and Nucynta ER — a single-point vulnerability spanning two core products. Commercialization is also geographically undiversified: all of the Nucynta Products and Symproic are sold exclusively in the United States, a structural rather than counterparty-specific exposure tied to the size of that single market. On the customer side, the company depends on wholesale pharmaceutical distributors for retail distribution, a dependency the filing frames at a lesser scale than the supply-side exposures. Taken together, the supply chain concentrations are the exposures most likely to matter to the verdict: losing the sole API supplier or Patheon's manufacturing capacity could disrupt multiple products simultaneously, whereas the U.S.-only footprint is a structural feature of the business rather than an idiosyncratic risk, and the distributor dependency is a comparatively smaller-scale link in the chain.
For the engine’s reasoning on COLL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| COLL● | Collegium Pharmaceutical, Inc. | 3 | 1 | 0 | 4 |
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| AMPH | Amphastar Pharmaceuticals, Inc. | 1 | 2 | 1 | 4 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.